Aurinia Pharmaceuticals (AUPH) stock plummeted 13.46% in the pre-market trading session on Thursday, following the release of the company's fourth-quarter 2024 earnings report and forward guidance.
Despite reporting better-than-expected Q4 earnings and revenue, with EPS of $0.01 beating analyst estimates of a $0.02 loss and revenue of $59.87 million exceeding forecasts of $59.7 million, investors were seemingly unimpressed with the company's performance.
While Aurinia swung to a full-year 2024 profit of $5.8 million after reporting a loss in the previous year, the company's forward guidance for 2025 revenue of $250-$260 million appears to have fallen short of market expectations, potentially triggering the sharp sell-off.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。